Actively Recruiting
Long-term Beta-blocker Therapy After Acute Myocardial Infarction
Led by Samsung Medical Center · Updated on 2025-12-29
2540
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
Sponsors
S
Samsung Medical Center
Lead Sponsor
K
Kangbuk Samsung Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI). Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.
CONDITIONS
Official Title
Long-term Beta-blocker Therapy After Acute Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject must be at least 19 years of age.
- Subject who have been continuing beta-blocker therapy for at least 1 year after acute myocardial infarction regardless of the time of diagnosis
- Subject is able to verbally confirm understandings of risks and benefits of this trial, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
You will not qualify if you...
- Subject whose left ventricle ejection fraction was less than 40% from echocardiography performed after acute myocardial infarction or who have never received echocardiography.
- Treatment history of heart failure
- Contraindication to beta-blocker therapy (history of symptomatic bronchial asthma or chronic obstructive pulmonary disease, 2nd or 3rd degree AV block, cardiac pacemaker implantation, or other cases where beta-blocker cannot be used under the judgment of the clinician)
- Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
- History of atrial fibrillation
- Pregnancy or breast feeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
J
Joo-Yong Hahn, MD,PhD
CONTACT
K
Ki Hong Choi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here